Finasteride Market Size by Key Players: Merck Sharp & Dohme, Sun Pharmaceuticals, Ranbaxy Laboratories, Aurobindo Pharma, Teva Pharmaceuticals, Actavis, Hetero Labs, Yabao Pharmaceuticals, Cipla, Yangtze River Pharma, Gedeon Richter, Nanjing Sanhome

U.S. finasteride market size may witness significant gains owing to its global dominance in alopecia treatment industry. North America generated over 2 billion revenue in alopecia market in 2015. Government approval to use finasteride in men hair loss treatment and other health problems accompanied by better results from other alternatives are influencing factors to foster regional growth.

Request for an in-depth table of contents for this report @ https://www.gminsights.com/request-toc/upcoming/732

As per American Hair Loss Association, globally approximately 750 thousand people are engaged in hair loss treatment and androgenetic alopecia accounted for more than 90% of hair loss among men in 2015. Coronary heart disease and prostate enlargement are primary reasons to cause this male pattern baldness. Moreover, prostate cancer, diabetes & obesity, and high blood pressure are other responsible factors to lead men hair loss.

Finasteride Market addresses hair loss, brought about by change in consumer eating habits, sedentary lifestyle and rise in stress levels. Blocking the male hormone testosterone and conversion into androgen dihydrotestosterone (DHT), which is responsible for hair loss is intrinsic property responsible for global finasteride market size growth.

Global alopecia (hair loss treatment) market was worth over USD 7 billion in 2015 and may surpass USD 11 billion valuation by 2024. Finasteride, being the solely oral medication approved by FDA for male hair loss treatment have an upper hand in alopecia market growth.

Major application includes treatment of benign prostatic hyperplasia (BPH), male pattern baldness, hormone replacement therapy. The product is demonstrated effective in men; it has contrary effects on female and children thus it is recommended to be not in touch with the medicine. In BPH, the prostate gland becomes larger in older men which causes problems with passing urine as it is situated near bladder.

Request for customization @ https://www.gminsights.com/roc/732

Finasteride shrinks an enlarged prostate in men which positively results in decreased urge to urinate, decreased night time urination, and less straining. The medication decreases the natural body hormone (DHT) amount in body which causes prostate growth. Effective results and no need for surgery are key reasons to drive demand in this segment.

Finasteride market share comprises of Merck Sharp & Dohme, Sun Pharmaceuticals, Ranbaxy Laboratories, Dr. Reddys Laboratories and Intas Pharmaceuticals. Other prominent companies include Aurobindo Pharma, Teva Pharmaceuticals, Actavis, Hetero Labs, Yabao Pharmaceuticals, Cipla, Yangtze River Pharma, Gedeon Richter, Nanjing Sanhome, Shandong Renhetang Hangzhou Conba Group, New Asia Pharma, and Qianjin Pharma.

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com

This release was published on openPR.